BioCentury
ARTICLE | Company News

Teva, OncoGenex unwind custirsen deal

December 31, 2014 1:50 AM UTC

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will pay OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) $27 million and return worldwide rights to custirsen sodium ( OGX-011) after the companies agreed to unwind a 2009 deal.

In April, custirsen missed the primary endpoint of the Phase III SYNERGY trial to treat metastatic castration-resistant prostate cancer (CPRC). Once-weekly doses of the second-generation antisense inhibitor of serum clusterin mRNA plus docetaxel and prednisone did not improve median overall survival (OS) vs. docetaxel and prednisone alone (23.4 vs. 22.2 months, p=0.207) in the 1,022-patient, open-label trial. ...